Organon & Co
OGN7.185USD
+0.095+1.34%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.87BMarket Cap
3.72P/E TTM
More Details of Organon & Co Company
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Organon & Co Info
Ticker SymbolOGN
Company nameOrganon & Co
IPO dateMay 14, 2021
CEOMorrissey (Joseph T)
Number of employees10000
Security typeOrdinary Share
Fiscal year-endMay 14
Address30 Hudson Street
CityJERSEY CITY
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code07302
Phone15514306000
Websitehttps://www.organon.com/
Ticker SymbolOGN
IPO dateMay 14, 2021
CEOMorrissey (Joseph T)
Company Executives of Organon & Co
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
144.48K
+8.57%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
71.89K
+18.29%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
59.92K
+10.11%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
52.85K
+17.96%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
41.33K
+26.65%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
By RegionUSD
Name
Revenue
Proportion
Europe and Canada
419.00M
26.29%
United States
414.00M
25.97%
Latin America, Middle East, Russia and Africa
285.00M
17.88%
Asia Pacific and Japan
250.00M
15.68%
China
204.00M
12.80%
Other
22.00M
1.38%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Women’s Health
462.00M
28.98%
Cardiovascular
283.00M
17.75%
Non-Opioid Pain, Bone and Dermatology
250.00M
15.68%
Respiratory
220.00M
13.80%
Other
206.00M
12.92%
Biosimilars
173.00M
10.85%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
Other
65.33%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
13.76%
BlackRock Institutional Trust Company, N.A.
10.68%
MFS Investment Management
3.63%
State Street Investment Management (US)
3.59%
LSV Asset Management
3.01%
Other
65.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.62%
Investment Advisor/Hedge Fund
20.77%
Hedge Fund
4.75%
Pension Fund
2.56%
Research Firm
2.06%
Bank and Trust
0.92%
Sovereign Wealth Fund
0.86%
Individual Investor
0.36%
Venture Capital
0.04%
Other
20.06%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1485
219.88M
84.58%
-37.41M
2025Q2
1527
205.34M
78.98%
-50.49M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
2023Q2
2016
205.94M
80.75%
-21.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
32.15M
12.37%
+2.54M
+8.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
28.28M
10.88%
-627.34K
-2.17%
Jun 30, 2025
MFS Investment Management
10.11M
3.89%
-469.39K
-4.44%
Jun 30, 2025
State Street Investment Management (US)
9.52M
3.66%
+540.48K
+6.02%
Jun 30, 2025
LSV Asset Management
7.99M
3.07%
+8.69K
+0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.40M
1.69%
-121.50K
-2.69%
Jun 30, 2025
Millennium Management LLC
9.09M
3.5%
+8.11M
+829.74%
Jun 30, 2025
AQR Capital Management, LLC
3.25M
1.25%
+1.88M
+136.10%
Jun 30, 2025
Gotham Asset Management, LLC
2.71M
1.04%
+1.31M
+93.22%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.63M
1.78%
+459.24K
+11.02%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Alger Russell Innovation ETF
1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.22%
First Trust Health Care Alphadex Fund
1.1%
Invesco S&P SmallCap Health Care ETF
1.07%
Brandes US Small-Mid Cap Value ETF
1.05%
iShares U.S. Pharmaceuticals ETF
0.65%
Lattice Hartford Multifactor Small Cap ETF
0.5%
WisdomTree U.S. SmallCap Dividend Fund
0.5%
Royce Quant Small-Cap Quality Value ETF
0.45%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.72%
Alger Russell Innovation ETF
Proportion1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.22%
First Trust Health Care Alphadex Fund
Proportion1.1%
Invesco S&P SmallCap Health Care ETF
Proportion1.07%
Brandes US Small-Mid Cap Value ETF
Proportion1.05%
iShares U.S. Pharmaceuticals ETF
Proportion0.65%
Lattice Hartford Multifactor Small Cap ETF
Proportion0.5%
WisdomTree U.S. SmallCap Dividend Fund
Proportion0.5%
Royce Quant Small-Cap Quality Value ETF
Proportion0.45%
Dividend
A total of
1.03B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Nov 10, 2025
OGN.NB Final Cash Dividend of gross USD 0.02 paid on Dec 11, 2025 going ex on Nov 20, 2025
Nov 20, 2025
Dec 11, 2025
Nov 20, 2025
Aug 05, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Sep 11, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 11, 2025
Aug 15, 2025
May 01, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 12, 2025 going ex on May 12, 2025
May 12, 2025
Jun 12, 2025
May 12, 2025
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
Aug 08, 2023
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 14, 2023
Aug 17, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Organon & Co?
The top five shareholders of Organon & Co are:
The Vanguard Group, Inc. holds 32.15M shares, accounting for 12.37% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 28.28M shares, accounting for 10.88% of the total shares.
MFS Investment Management holds 10.11M shares, accounting for 3.89% of the total shares.
State Street Investment Management (US) holds 9.52M shares, accounting for 3.66% of the total shares.
LSV Asset Management holds 7.99M shares, accounting for 3.07% of the total shares.
The Vanguard Group, Inc. holds 32.15M shares, accounting for 12.37% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 28.28M shares, accounting for 10.88% of the total shares.
MFS Investment Management holds 10.11M shares, accounting for 3.89% of the total shares.
State Street Investment Management (US) holds 9.52M shares, accounting for 3.66% of the total shares.
LSV Asset Management holds 7.99M shares, accounting for 3.07% of the total shares.
What are the top three shareholder types of Organon & Co?
The top three shareholder types of Organon & Co are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
MFS Investment Management
How many institutions hold shares of Organon & Co (OGN)?
As of 2025Q3, 1485 institutions hold shares of Organon & Co, with a combined market value of approximately 219.88M, accounting for 84.58% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 5.59%.
What is the biggest source of revenue for Organon & Co?
In FY2025Q2, the Women’s Health business generated the highest revenue for Organon & Co, amounting to 462.00M and accounting for 28.98% of total revenue.
